High-dose lymphoablative therapy (HDLT) with or without stem-cell rescue for treatment of severe autoimmune diseases

BlueCross BlueShield Association
Record ID 32003000728
Authors' objectives:

This Assessment summarizes published evidence from pilot studies and phase I/II trials of high-dose lymphoablative therapy with or without autologous stem-cell rescue for the treatment of severe autoimmune disease to determine the procedures effect on health outcomes.

Authors' methods: Systematic review
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Autoimmune Diseases
  • Hematopoietic Stem Cell Transplantation
  • Immunosuppressive Agents
Organisation Name: BlueCross BlueShield Association
Contact Address: BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name: tec@bcbsa.com
Contact Email: tec@bcbsa.com
Copyright: BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.